← Back to Search

Anti-inflammatory

Treatment Sequence 2 for Osteoarthritis

Phase 2
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 10 Other Conditions

Summary

PH-797804 is a potent inhibitor of inflammatory mediators that have a potential role in pain signalling following nerve injury and inflammation. Blocking such mediators may potentially have a therapeutic benefit by reducing pain.

Eligible Conditions
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Treatment Sequence 4Experimental Treatment2 Interventions
Group II: Treatment Sequence 3Experimental Treatment2 Interventions
Group III: Treatment Sequence 2Experimental Treatment2 Interventions
Group IV: Treatment Sequence 1Experimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Naproxen
FDA approved
PH-797804
Not yet FDA approved
PH-797804
Not yet FDA approved
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,658 Previous Clinical Trials
17,877,253 Total Patients Enrolled
48 Trials studying Osteoarthritis
28,529 Patients Enrolled for Osteoarthritis
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,544 Previous Clinical Trials
14,918,429 Total Patients Enrolled
49 Trials studying Osteoarthritis
36,781 Patients Enrolled for Osteoarthritis
~11 spots leftby Nov 2025